Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

More recent frailty assessments predict mortality better in seniors

29 Jul 2019

Frailty is a good predictor of mortality risk in the elderly for up to 10 years, with more recent assessments resulting in improved predictions, a recent study has found.

Researchers performed a population-based cohort study on 909 community-dwelling elderly adults (mean age, 74.4±6.2 years; 55 percent female), of whom 549 underwent frailty assessments at two time points. Frailty was measured using the frailty phenotype (FP) and frailty index (FI).

Over a 10-year follow-up period, 292 deaths were reported, yielding a 33.8-percent mortality rate. This was higher in males (40.1 percent vs 28.6 percent) and for those aged ≥75 years (vs 65–74 years; 54.3 percent vs 17.8 percent). Participants in the lowest income bracket were also more likely to die than their counterparts in the highest group (35.5 percent vs 11.6 percent).

According to FP, 18.3 percent of the participants were frail at baseline. The corresponding figure according to FI was 48.1 percent. In both scales, mortality rates grew with increasing levels of frailty.

For instance, 60.2 percent of those defined by FP as frail died by 10 years, as opposed to only 26.3 percent of nonfrail seniors. In FI, 45.1 percent of those who were frail died by 10 years, much higher than the 21.4 percent mortality rate in the nonfrail participants.

In those with a second frailty assessment, follow-up findings were a stronger predictor of mortality than baseline frailty results.

“Although frailty measurement was a significant predictor of mortality risk up to 10 years, recency of measurement was a stronger predictor,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.